



25 **Abstract**

26 **Objective:** To evaluate differences by race/ethnicity in clinical characteristics and outcomes  
27 among hospitalized patients with Covid-19 at Massachusetts General Hospital (MGH).

28 **Methods:** The MGH Covid-19 Registry includes confirmed SARS-CoV-2-infected patients  
29 hospitalized at MGH and is based on manual chart reviews and data extraction from electronic  
30 health records (EHRs). We evaluated differences between White/Non-Hispanic and Hispanic  
31 patients in demographics, complications and 14-day outcomes among the N=866 patients  
32 hospitalized with Covid-19 from March 11, 2020 - May 4, 2020.

33 **Results:** Overall, 43% of patients hospitalized with Covid-19 were women, median age was 60.4  
34 [IQR = (48.2, 75)], 11.3% were Black/non-Hispanic and 35.2% were Hispanic. Hispanic  
35 patients, representing 35.2% of patients, were younger than White/non-Hispanic patients  
36 [median age 51y; IQR = (40.6, 61.6) versus 72y; (58.0, 81.7) ( $p < 0.001$ )]. Hispanic patients were  
37 symptomatic longer before presenting to care (median 5 vs 3d,  $p = 0.039$ ) but were more likely to  
38 be sent home with self-quarantine than be admitted to hospital (29% vs 16%,  $p < 0.001$ ). Hispanic  
39 patients had fewer comorbidities yet comparable rates of ICU or death (34% vs 36%).  
40 Nonetheless, a greater proportion of Hispanic patients recovered by 14 days after presentation  
41 (62% vs 45%,  $p < 0.001$ ; OR = 1.99,  $p = 0.011$  in multivariable adjusted model) and fewer died  
42 (2% versus 18%,  $p < 0.001$ ).

43 **Conclusions:** Hospitalized Hispanic patients were younger and had fewer comorbidities  
44 compared to White/non-Hispanic patients; despite comparable rates of ICU care or death, a  
45 greater proportion recovered. These results have implications for public health policy and the  
46 design and conduct of clinical trials.

47

## 48 **Introduction**

49 Massachusetts has over 110,000 cumulative confirmed Covid-19 cases and over 8000 deaths as  
50 of August 2, 2020.<sup>1</sup> The Massachusetts epidemic has a high degree of geographic and  
51 racial/ethnic heterogeneity in reported cases, even among cities with similar population density.<sup>2</sup>  
52 The disproportionate burden of Covid-19 borne by some communities has been attributed to  
53 higher proportion of essential workers in public facing jobs, greater household size, and poverty  
54 limiting access to care.<sup>3-5</sup> Our objective was to compare clinical and demographic characteristics,  
55 complications and 14-day outcomes among Covid-19 patients hospitalized at Massachusetts  
56 General Hospital (MGH) by race and ethnicity. MGH is a quaternary care facility with the  
57 largest number of hospitalized and intensive care unit (ICU) patients with Covid-19 in the state.

58

## 59 **Methods**

60 The MGH Covid-19 Data Registry includes confirmed SARS-CoV-2-infected patients  
61 hospitalized at MGH and is based on manual chart reviews and data extraction from electronic  
62 health records (EHRs). Trained reviewers collected demographics, known SARS-CoV-2  
63 epidemiologic risk factors (e.g., an exposure in a nursing home), comorbid conditions,  
64 medications, Covid-19 related symptoms, and laboratory tests. Outcome of initial presentation to  
65 care (PTC), transfer to ICU, complications of Covid-19 disease, and 14-day clinical status were  
66 also extracted by manual review. PTC was defined as first contact with health care system with  
67 Covid-19 symptoms. The NIAID ordinal clinical outcome scale at 14 days from initial PTC was  
68 measured.<sup>6</sup> This report compares clinical and demographic characteristics, complications and 14-  
69 day outcomes for N=866 Covid-19 PCR positive patients hospitalized at MGH from March 11,  
70 2020 - May 4, 2020.

71 We present results overall and stratified by self-identified race/ethnicity, with statistical testing  
72 comparing Hispanics and White/non-Hispanics. Tests of proportions (for binary outcomes) and t-  
73 tests (for numeric traits) were applied. All tests are two-sided and a p-value less than 0.05 was  
74 considered statistically meaningful. A multivariable logistic regression was fitted for a favorable  
75 outcome defined as hospital discharge or not requiring supplemental oxygen (ordinal score = 1-  
76 3) at 14 days after PTC within the subset of individuals who were neither admitted to the ICU  
77 nor dead within this time frame. We evaluated the association of race/ethnicity with this outcome  
78 after adjusting for age, sex, body mass index (BMI), and smoking.

79  
80 We additionally considered the degree of missing EHR data overall and by race/ethnicity among  
81 all Covid-19 confirmed cases hospitalized at MGH. Availability of BMI in the EHR over the past  
82 3 years and number of visits per year were used as proxies for having prior comorbidity data that  
83 could inform Covid-19 risk factors and eligibility for clinical trials. The MGH Covid registry  
84 was approved by the Partners HealthCare Institutional Review Board (Protocol #2020P000829).  
85 Because this work was limited to chart review, individual consent was not obtained.

86

## 87 **Results**

88 Overall, 43% of patients hospitalized with Covid-19 were women, median age was 60.4 [IQR =  
89 (48.2, 75)], 11.3% were Black/non-Hispanic and 35.2% were Hispanic (Table 1). Hispanic  
90 patients were younger than White/non-Hispanic patients [median age 51.1 years; IQR = (40.6,  
91 61.6) versus 72 years; (58.0, 81.7) ( $p < 0.001$ )], less often ever smokers (23% vs 53%,  $p < 0.001$ )  
92 and more often had no known epidemiologic exposure (49% versus 35%  $p < 0.001$ ) (Table 1).  
93 Hispanics were symptomatic for slightly longer before presenting (median 5 versus 3 days,

94 p=0.039) and more commonly reported Covid-19 symptoms but were more likely to be sent  
 95 home with self-quarantine rather than admitted to hospital at initial evaluation (29% versus 16%,  
 96 p<0.001). Documented co-morbidities were less common among Hispanics (e.g., 37% of  
 97 Hispanics vs 62% of White/non-Hispanics had a history of hypertension, p<0.001). Absolute  
 98 lymphocyte count was higher and d-dimer lower on average among Hispanics at hospitalization  
 99 (p<0.001), while ferritin was higher among Hispanics compared to White/non-Hispanics  
 100 (p=0.024).

101

102 **Table 1.** Risk factors and complications overall and by race/ethnicity<sup>(a)</sup>  
 103

	<i>Overall</i> (N=866)	<i>White/ Non-Hispanic</i> (N=346)	<i>Black/ Non-Hispanic</i> (N=98)	<i>Hispanic</i> (N=305)	<i>P-value for test of White vs. Hispanic</i>
<b>Presentation to Care (PTC)</b>					
Female sex – count/total (%)	375/866(0.43)	147/346(0.42)	51/98(0.52)	138/305(0.45)	0.529
Age – Median (IQR)	60.4 (48.2,75)	72 (58,81.7)	62.8 (52.8,72.3)	51.1 (40.6,61.6)	<0.001
Age >65	359/863(0.42)	217/346(0.63)	40/98(0.41)	60/305(0.20)	<0.001
Smoker (ever)	329/861(0.38)	184/345(0.53)	38/98(0.39)	70/301(0.23)	<0.001
Body Mass Index	29.1 (25.6,33.9)	27.9 (24.8,33.4)	28.8 (25,32.5)	30.7 (26.6,34.8)	0.030
No known epidemiologic risk	351/866(0.41)	120/346(0.35)	37/98(0.38)	148/305(0.49)	<0.001
Time from Symptoms to PTC	4 (2,7)	3 (1,7)	3 (1,7)	5 (3,8)	0.039
Fever	567/866(0.65)	191/346(0.55)	55/98(0.56)	231/305(0.76)	<0.001
Cough without sputum	451/866(0.52)	164/346(0.47)	45/98(0.46)	176/305(0.58)	0.011
Dyspnea	466/866(0.54)	170/346(0.49)	49/98(0.5)	178/305(0.58)	0.023
Myalgia/Arthralgia	332/866(0.38)	100/346(0.29)	29/98(0.3)	151/305(0.5)	<0.001
Diarrhea, nausea or vomiting	286/866(0.33)	100/346(0.29)	29/98(0.3)	121/305(0.4)	0.005
Statins	362/866(0.42)	187/346(0.54)	33/98(0.34)	93/305(0.3)	<0.001
ACE Inhibitors or ARBs	206/866(0.24)	91/346(0.26)	26/98(0.27)	60/305(0.2)	0.057
Cardiac/metabolic disease history	685/865(0.79)	295/346(0.85)	85/98(0.87)	216/304(0.71)	<0.001
Hypertension	451/866(0.52)	215/346(0.62)	65/98(0.66)	114/305(0.37)	<0.001
Dyslipidemia	324/866(0.37)	150/346(0.43)	36/98(0.37)	93/305(0.3)	0.001
Pulmonary disease history	270/862(0.31)	145/343(0.42)	30/98(0.31)	64/304(0.21)	<0.001
Diabetes (DM) type 2	299/866(0.35)	118/346(0.34)	42/98(0.43)	96/305(0.31)	0.529
<b>Outcome at PTC</b>					

Home with self-quarantine	184/866(0.21)	55/346(0.16)	15/98(0.15)	87/305(0.29)	<0.001
Admitted to hospital	528/866(0.61)	229/346(0.66)	63/98(0.64)	176/305(0.58)	0.032
Admitted to ICU	118/866(0.14)	41/346(0.12)	13/98(0.13)	36/305(0.12)	1.000
<b>Admission labs<sup>(b)</sup></b>					
Absolute lymphocyte count < 0.80	295/808(0.37)	158/326(0.48)	25/93(0.27)	71/281(0.25)	<0.001
CRP > 100	294/781(0.38)	104/314(0.33)	36/92(0.39)	101/272(0.37)	0.353
D-Dimer > 1000	371/753(0.49)	164/297(0.55)	56/87(0.64)	107/267(0.40)	<0.001
Ferritin > 500	400/787(0.51)	142/315(0.45)	41/92(0.45)	150/274(0.55)	0.024
<b>Follow-up (14 day)</b>					
In ICU or death during follow-up	311/855(0.36)	125/343(0.36)	33/98(0.34)	101/301(0.34)	0.494
ICU during follow-up <sup>(c)</sup>	264/858(0.31)	86/343(0.25)	30/98(0.31)	98/301(0.33)	0.044
Death during follow-up	88/860(0.1)	61/346(0.18)	11/98(0.11)	7/302(0.023)	<0.001
ARDS	199/863(0.23)	69/346(0.20)	18/98(0.18)	72/302(0.24)	0.269
Liver dysfunction	138/863(0.16)	44/346(0.13)	12/98(0.12)	57/302(0.19)	0.041
Acute renal injury/failure	175/863(0.20)	79/346(0.23)	24/98(0.24)	46/302(0.15)	0.019
Ordinal Outcome Score <sup>(d)</sup> = 1-3	463/860(0.54)	153/343(0.45)	59/98(0.60)	188/302(0.62)	<0.001
Ordinal Outcome Score = 4-5	155/860(0.18)	84/343(0.24)	9/98(0.092)	43/302(0.14)	0.002
Ordinal Outcome Score = 6-8	242/860(0.28)	106/343(0.31)	30/98(0.31)	71/302(0.24)	0.044

104 <sup>(a)</sup>Race/ethnicity breakdown: Additional patient categories not included in table: Asian (n=27), Other (n=22),  
105 Missing (n=64), Native Hawaiian or other Pacific Islander (n=1), American Indian or Alaska Native (n=3). Results  
106 are not reported separately for these categories due to the limited sample size. <sup>(b)</sup>Lab recorded within +/-3 days of  
107 hospital admission. <sup>(c)</sup> 47 patients died without being admitted to the ICU (39 White, 3 Hispanic, 3 Black, 1 Asian, 1  
108 Missing). <sup>(d)</sup>Score: 8 – death; 7 – hospitalized, on invasive mechanical ventilation or ECMO; 6 – hospitalized, on  
109 non-invasive ventilation or high flow oxygen; 5 – hospitalized requiring supplemental oxygen; 4 – hospitalized, not  
110 requiring supplemental oxygen, requiring ongoing medical care; 3 – hospitalized, not requiring oxygen, no longer  
111 requiring ongoing medical care; 2 – not hospitalized, limitation on activities and/or requiring home oxygen; 1 – not  
112 hospitalized, no limitations on activities  
113  
114 During the study period, ICU bed capacity was sufficient. In the 14 days following presentation  
115 to care, 36% of patients went to the ICU or died prior to going to the ICU. Although a  
116 comparable proportion of Hispanics and White/non-Hispanics received ICU care or died (34%  
117 versus 36%) and experienced ARDS (24% versus 20%), a larger proportion of Hispanics

118 experienced liver dysfunction (19% vs 13%,  $p=0.041$ ) and a smaller proportion had acute renal  
119 injury/failure (15% versus 23%,  $p=0.019$ ). While there were few deaths by 14 days from PTC  
120 (N=88, 10%), a smaller proportion of Hispanic patients had died compared to White/non-  
121 Hispanic patients (2% versus 18%,  $p<0.001$ ). A larger proportion of Hispanics had the best  
122 outcome score at 14 days (score 1-3, 62% versus 45%,  $p<0.001$ ). Among patients neither  
123 admitted to the ICU nor dead within 14 days of PTC, Hispanics were significantly more likely to  
124 have the best outcome score (OR=1.99,  $p=0.011$ ) compared to White/non-Hispanics after  
125 controlling for age, sex, BMI and smoking status.

126  
127 Many hospitalized patients, and disproportionately Hispanic patients, were new to our health  
128 system, as measured by availability of BMI in the EHR. A smaller proportion of Hispanics than  
129 White/non-Hispanics had a BMI measurement in the EHR in 2019 (37% versus 62%) and for the  
130 three-year period 2017-2019 (16% versus 40%). The median number of months since first  
131 contact was 20.5 for Hispanics and 69.0 for White/non-Hispanics and Hispanic patients had  
132 fewer visits/year among years with available data (1.5 versus 2.3).

133

## 134 **Discussion**

135 Among patients hospitalized for Covid-19 at MGH, 35% were Hispanic, although Hispanic  
136 patients comprised 8% of inpatient discharges at MGH in 2017.<sup>7</sup> Hispanic patients were younger  
137 with fewer comorbidities associated with severe Covid-19 disease, yet had comparable rates of  
138 ICU care or death as White/non-Hispanics.<sup>8</sup> Despite similarly severe clinical courses, a greater  
139 proportion of Hispanics recovered by 14 days after PTC and fewer died. While older age is  
140 associated with hospitalization for Covid-19 infection in the US, hospitalized Hispanic patients

141 in our sample were substantially younger than their White/non-Hispanic counterparts.<sup>9</sup> Older  
142 patients may have been more likely to have “do not intubate” directives and thus be less likely to  
143 transfer to the ICU; we therefore used the composite severe outcome of ICU or death to  
144 minimize confounding. Hispanics had fewer comorbidities and were less likely to experience  
145 acute kidney injury and these may explain the better clinical outcomes that we observed.  
146 However, longer term follow-up and judicious consideration of additional information, including  
147 age<sup>10</sup> and socioeconomic factors<sup>11</sup> are needed to better evaluate the significance of these  
148 findings.

149  
150 A strength of this study was the use of manual chart review for identifying comorbid conditions.  
151 We found that fewer Hispanic patients had data in our EHR in the three years preceding the  
152 appearance of SARS-CoV-2. Underreporting of pre-existing comorbidities in observational  
153 studies, from limited EHR data or under-diagnosis, can bias the relationship between  
154 comorbidities and clinical outcomes differentially across marginalized groups.<sup>12</sup> This must be  
155 considered when studies rely on EHR data for assessing Covid-19 risk factors or clinical  
156 outcomes. A limitation of this study is that due to sample size, we were unable to meaningfully  
157 assess differences among other racial and ethnic groups.

158  
159 Hispanics are disproportionately impacted by Covid-19 and have a severe disease despite  
160 younger age and fewer documented comorbidities. This underscores the urgent need to report  
161 disaggregated outcomes to better understand Covid-19 among racial/ethnic groups. The design  
162 and practice of clinical trials for treatments and vaccines can benefit from a deeper understanding  
163 of the profound heterogeneity of the populations Covid-19 impacts. As measures are taken to

164 fortify public health infrastructure in the United States, consideration of potential racial/ethnic  
165 differences in presentation and access to care as well as in clinical outcomes is essential to the  
166 reduction of health disparities.

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189 **Acknowledgements**

190 The authors gratefully acknowledge the dedicated manual chart reviewers and experienced data managers

191 for their methodological expertise, time and effort.

192

193

## 194 **References**

- 195 1. Massachusetts Department of Public Health COVID-19 Dashboard - August 2, 2020.  
196 Published online August 2, 2020. [https://www.mass.gov/doc/covid-19-dashboard-august-2-](https://www.mass.gov/doc/covid-19-dashboard-august-2-2020/download)  
197 [2020/download](https://www.mass.gov/doc/covid-19-dashboard-august-2-2020/download)
- 198 2. Massachusetts Department of Public Health - COVID-19 cases by city/town in MA - May  
199 13, 2020. [https://www.mass.gov/doc/confirmed-covid-19-cases-in-ma-by-citytown-january-](https://www.mass.gov/doc/confirmed-covid-19-cases-in-ma-by-citytown-january-1-2020-may-13-2020-0/download)  
200 [1-2020-may-13-2020-0/download](https://www.mass.gov/doc/confirmed-covid-19-cases-in-ma-by-citytown-january-1-2020-may-13-2020-0/download)
- 201 3. Webb Hooper M, Nápoles AM, Pérez-Stable EJ. COVID-19 and Racial/Ethnic Disparities.  
202 *JAMA*. Published online May 11, 2020. doi:10.1001/jama.2020.8598
- 203 4. Haynes N, Cooper LA, Albert MA. At the Heart of the Matter: Unmasking and Addressing  
204 COVID-19's Toll on Diverse Populations. *Circulation*. Published online May 4,  
205 2020:CIRCULATIONAHA.120.048126. doi:10.1161/CIRCULATIONAHA.120.048126
- 206 5. U.S. Census Bureau. American Community Survey. Published 2017.  
207 <https://datausa.io/profile/geo/chelsea-ma/>
- 208 6. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 —  
209 Preliminary Report. *N Engl J Med*. Published online May 22, 2020:NEJMoa2007764.  
210 doi:10.1056/NEJMoa2007764
- 211 7. Betancourt JR, Tan-McGrory A, Kenst KS, et al. ANNUAL REPORT ON EQUITY IN  
212 HEALTH CARE QUALITY 2018–2019. Published online 2018:52.
- 213 8. Petrilli CM, Jones SA, Yang J, et al. *Factors Associated with Hospitalization and Critical*  
214 *Illness among 4,103 Patients with COVID-19 Disease in New York City*. *Intensive Care and*  
215 *Critical Care Medicine*; 2020. doi:10.1101/2020.04.08.20057794
- 216 9. Garg S, Kim L, Whitaker M, et al. Hospitalization Rates and Characteristics of Patients  
217 Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 — COVID-NET, 14  
218 States, March 1–30, 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(15):458-464.  
219 doi:10.15585/mmwr.mm6915e3
- 220 10. Gross CP, Essien UR, Pasha S, Gross JR, Wang S, Nunez-Smith M. *Racial and Ethnic*  
221 *Disparities in Population Level Covid-19 Mortality*. *Epidemiology*; 2020.  
222 doi:10.1101/2020.05.07.20094250
- 223 11. Chowkwanyun M, Reed AL. Racial Health Disparities and Covid-19 — Caution and  
224 Context. *N Engl J Med*. Published online May 6, 2020:NEJMp2012910.  
225 doi:10.1056/NEJMp2012910
- 226 12. Weber GM, Adams WG, Bernstam EV, et al. Biases introduced by filtering electronic health  
227 records for patients with “complete data.” *Journal of the American Medical Informatics*  
228 *Association*. 2017;24(6):1134-1141. doi:10.1093/jamia/ocx071

229

230

231

232

233

234

235

236